Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 26, 2023
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
Journal: Genome medicine
Published: August 17, 2023
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.
Journal: International journal of cancer
Published: December 16, 2022
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.
Journal: Cancer reports (Hoboken, N.J.)
Published: September 10, 2021
Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.
Journal: Cancer research
Published: April 02, 2021
A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.
Journal: International journal of cancer
Published: March 04, 2020
Maintenance DFMO Increases Survival in High Risk Neuroblastoma.
Journal: Scientific reports
Published: July 13, 2018
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma.
Journal: Pediatric blood & cancer
Published: February 10, 2015
Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.
Journal: Cancer medicine
Published: October 23, 2014
Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
Journal: Translational research : the journal of laboratory and clinical medicine
Published: November 08, 2013
Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance.
Journal: Pediatric blood & cancer
Published: November 05, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026